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Abstract
Background. Health-related qualityof life (QOL) is an im-
portant outcome for older people who are often on dialysis
for life. Little is, however, known about differences in QOL
onhaemodialysis(HD)andperitoneal dialysis(PD)inolder
age groups. Randomising patients to either modality to
assess outcomes is not feasible.
Methods. In this cross-sectional, multi-centred study we
conducted QOL assessments (Short Form-12 Mental and
Physical Component Summary scales, Hospital Anxiety
and Depression Scale and Illness Intrusiveness Ratings
Scale) in 140 people (aged 65 years or older) on PD
and HD.
Results. The groups were similar in age, gender, time on
dialysis, ethnicity, Index of Deprivation (based on post-
code), dialysis adequacy, cognitive function (Mini-Mental
State Exam and Trail-Making Test B), nutritional status
(Subjective Global Assessment) and social networks.
There was a higher comorbidity score in the HD group.
Regression analyses were undertaken to ascertain which
variables significantly influence each QOL assessment.
All were influenced by symptom count highlighting that
the patient’s perception of their symptoms is a critical
determinant of their mental and physical well being.
Modality was found to be an independent predictor
of illness intrusion with greater intrusion felt in those
on HD.
Conclusions. Overall, in two closely matched demograph-
ic groups of older dialysis patients, QOL was similar, if not
better, in those on PD. This study strongly supports offer-
ing PD to all suitable older people.
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Introduction
There is remarkably little information about how older pa-
tients cope with living on dialysis, despite the fact that the
incident rate of starting dialysis increases with age, with
rates of 113–221 per million age-related population for
45–64 year olds compared to 110–610 for 65–74 year olds
and 99–984 for those over 75 years [1]. Not surprisingly
therefore, the dialysis population is old with a median
age mostly in the 60s and even over 70 years in some Eu-
ropean regions [2]. In most countries, older patients are
less likely to start on peritoneal dialysis (PD) compared
to younger patients, even in countries with a relatively high
use of PD. Thus, 13–25% of patients aged 65–74 years and
9–13% for those aged >75 years start on PD in Denmark,
Belgium, the Netherlands and the United Kingdom com-
pared to 20–41% of patients aged 45–64 years [2]. This
observation is not true for all countries; in Australia,
the prevalence of PD in the dialysis population is 20–
23% across all age groups, though it does fall to 13%
for those aged over 85 years [3]. As patients receive their
information about dialysis mainly from their healthcare
team, any bias against PD amongst individual doctors
and nurses is likely to influence choice of dialysis modal-
ity by patients. This is reflected in the large variability
seen between individual units within the same country;
as an example, in the UK, the percentage of incident pa-
tients over 65 years old starting on PD varies from 5 to
55% [4].
PD is a continuous home-based therapy, which offers
several potential advantages in older people. It is poten-
tially less disruptive for a patient’s and their family’s life-
style. Patients also avoid the need for transport (which is
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ysis unit three times a week. Furthermore, the rapid
changes in haemodynamic and fluid status associated
with haemodialysis (HD) are often poorly tolerated by
older patients who often comment on feeling ‘washed
out’ after a dialysis session. Indeed, even in younger
patients, it takes an average of 6 h to recover from a
standard HD session [5].
Many older patients do not have the opportunity for
transplantation, so quality of life (QOL) is particularly im-
portant. Most studies on QOL have examined the dialysis
population as a whole and have not been restricted to spe-
cific age groups. These studies have indicated potential ad-
vantages of both PD and HD [6–8]. The North Thames
Dialysis Study, which was a prospective study of incident
and prevalent patients starting on dialysis over the age of
70 years, is remarkably the only study to have focused on
older patients. The striking feature of the patients studied
was the high proportion on PD which reflected UK prac-
tice at the time of the actual study (late 1990s). With the
increase in satellite HD, many of these patients would now
not receive PD today in the UK, even though the results
showed that outcomes—survival and QOL—were not dif-
ferent for patients on HD and PD [9,10].
The largest study looking at choice of dialysis modality
whenpatientsaregivenfreechoiceistheNECOSAD(Neth-
erlands Cooperative Study on the Adequacy of Dialysis)
study. About a third of 1347 patients were deemed to have
medical or social contraindications to a particular modality,
predominantly PD. Of the two-thirds who were given a
choice, the principal characteristics associated with not
choosing PD were older age, being female and living alone.
Patients who were 70 years or older were six times more
likely to choose HD than those aged between 18 and
40 years, though patients who had received predialysis care
weremuchmorelikelytochoosePDthanthosewhohadnot
[11].
Older patients with end-stage kidney disease often have
considerable comorbidity, not only the vascular disease as-
sociated with their renal disease, but also the comorbidity
found in many older people, including impaired vision,
deafness, poor mobility, arthritis and cognitive dysfunc-
tion. They are often socially isolated, live in poor accom-
modations and may have financial problems. Depression is
common among patients on dialysis, occurring in 15–25%
patients [12,13], and possibly is even more common in
older patients with one small French study suggesting a
prevalence of 61% in HD patients aged over 70 years
[14]. This compares with <10% in a community-dwelling
elderly population [15]. This high rate of depression will
impact on QOL and has been shown to be related to func-
tional impairment and life satisfaction [16]. There are no
comparative data about depression for older PD patients.
BOLDE (Broadening Options for Long-term Dialysis in
the Elderly) is a multicentre study in the UK whose main
aim is to enable a higher proportion of older patients to
receive the dialysis modality of their choice. The first part
of the study, which we report here, is to determine QOL,
depression, symptoms and illness intrusion in older
(≥65 years) patients on PD compared to HD so that this
information can be given to future patients when choosing
their dialysis modality. As shown by the NECOSAD study
[11], randomised controlled trials to compare outcomes
between HD and PD are not feasible. We have therefore
aimed to achieve comparable groups by matching HD pa-
tients to existing PD patients.
Materials and methods
Patients were recruited from three hospitals in South East England: Ham-
mersmith Hospital in London, St Helier Hospital in Surrey and the Lister
Hospital in Stevenage. The three units vary in size with numbers of prev-
alent HD/PD patients on 31 December 2007 being 1056/67, 561/128 and
329/43, respectively, with 6.3, 13.5 and 19.0% new patients ≥65 years old
starting on PD [4].
Ethical approval was obtained from Charing Cross Research Ethics
Committee (06/Q0411/137). Data were collected between November
2007 and January 2009. A target recruitment of 70 matched pairs of
PD and HD patients was set as this was the maximum number of older
PD patients thought to be obtainable from the three renal units.
Inclusion and exclusion criteria
All patients recruited were aged 65 years and over, had been on dialysis
for a minimum of 90 days and had not been hospitalised for 30 days.
Patients with clinically obvious cognitive impairment (as assessed by ei-
ther the lead nephrologist or nurse responsible for the patient’s renal care)
or with a life expectancy of <6 months were excluded from the study.
Subjects and recruitment
Purposeful recruitment was undertaken to achieve comparable PD and
HD groups. The PD patient was recruited first (due to smaller numbers)
and matched to an HD patient with similar demographic characteristics:
age, gender, time on dialysis (total time excluding episodes of transplan-
tation), ethnicity and socio-economic status as determined by the Index of
Deprivation 2007 based on postcode [17]. Where more than one HD pa-
tient was identified as a possible match for the PD patient, the lead ne-
phrologist or nurse made a purposive selection. The patient groups were
therefore closely matched to each other by characteristics predominantly
seen in our PD population.
Baseline demographic and clinical data
Demographic (Table 1) and clinical data (Table 2) were collected from the
patients’ medical records and during the assessment. The Stoke–Davies
comorbidity score was used. The most recent routine blood test results
and dialysis adequacy values were recorded. Adequate dialysis was de-
fined as either an equilibrated Kt/V of >1.2 (two pool), a single pool
Kt/V of ≥1.4 and urea reduction ratio of >65% for HD patients or a
Kt/V of >1.7 for those on PD [4]. We defined late referrals as patients
who commenced dialysis <30 days after being assessed by a nephrologist.
This definition aims to identify those patients who were the least likely to
be prepared for dialysis. The late referral time span is reported to vary
between 30 days and 3–4 months [18], with the UK Renal Registry Re-
port specifying 90 days prior to starting dialysis [4].
Study visit
There was one off-study visit that took ∼1 h and consisted of sequential
cognitive, QOL and nutritional assessments (with the exception of one
patient who needed to be seen twice due to time constraints). All assess-
ments were conducted by the same researcher thereby eliminating inter-
observer variability. All were conducted in English except for one patient
where an interpreter was used. For those on HD, assessments were con-
ducted on a non-dialysis day or before dialysis. Each assessment was per-
formed in a private room within a hospital or satellite unit. The researcher
had received training on administering the assessments. To minimise bias,
3756 E.A. Brown et al.the researcher followed a script that ensured consistency of delivery of the
assessments to all patients.
Clinical assessments
(i) Cognitive function: Mini-Mental State Examination (MMSE): this
test is routinely used in clinical practice [19]. It is effective in de-
tecting cognitive impairment but is not sensitive to small changes in
cognitive function. Normative data are available, stratified into age
groups and education levels [20]. Scores are measured from 1 to 30,
with a score of 23 or below suggesting cognitive impairment. The
non-completion rate of the MMSE in this study was 1.5% due to
language barriers and poor visual acuity.
Trail-Making Test B (TMT-B): this test assesses areas of executive
function and cognition and was selected as it is more discriminatory
than the MMSE. Normative data are stratified into age groups and
years of education and are used to evaluate performance [21]. The
non-completion rate of the TMT-B was 13% in this study due to
language barriers (0.7%), poor acuity (4.3%), unable to complete
(4.3%), interruption (1.4%), difficulties using pen and paper
(0.7%) and refusal (1.4%).
Table 1. Patient characteristics
Participants
Difference between PD
and HD participants Non-participants
Difference between
participants
and non-participants
PD (n=70) HD (n=70) P-value PD (n=18) HD (n=28) P-value PD/HD
Demography
Mean age years (SD) 73.1 (5.5) 73.4 (5.1) 0.812
a 73.8 (5.6) 73.5 (5.5) 0.611/0.972
c
65–69 years, n 21 (30%) 21 (30%) 5 (28%) 7 (25%)
70–79 years, n 41 (59%) 41 (59%) 10 (56%) 17 (61%)
80–89 years, n 8 (11%) 8 (11%) 3 (17%) 4 (14%)
Male sex, n 49 (70%) 49 (70%) 1.000
b 6 (33%) 17 (61%) 0.004/0.376
b
Non-Caucasian, n 3 (4%) 7 (10%) 0.189
b 5 (28%) 3 (11%) 0.002/0.916
b
Mean index of deprivation (SD) 13.7 (11.3) 13.7 (8.7) 0.476
c –– –
Mean years of education (SD) 11.7 (3.5) 11.7 (3.6) 0.983
c –– –
Living alone, n 16 (23%) 18 (26%) 0.321
b –– –
Mean social network score (SD) 15.2 (4.4) 14.9 (4.0) 0.630
a
Mean time on dialysis months (SD) 30.5 (28.3) 31.4 (26.5) 0.480
c 25.8 (21.3) 34.1 (31.5) 0.627/0.820
c
3–12 months on dialysis 23 (33%) 18 (26%) 8 (44%) 11 (39%)
>12–36 months on dialysis 26 (37%) 31 (44%) 5 (28%) 6 (21%)
>36 months on dialysis 21 (30%) 21 (30%) 5 (28%) 11 (39%)
aIndependent t-test.
bPearson chi-square test.
cMann–Whitney test.
Table 2. Clinical demographics
PD HD P-value
n
% or Mean
(SD) n
% or Mean
(SD)
Difference between
PD and HD
Clinical characteristics
Stoke–Davies comorbidity count
0 comorbidities 15 21% 12 17% 0.520
1–2 comorbidities 46 66% 34 49% 0.040
≥3 comorbidities 9 13% 24 34% 0.003
Median Stoke–Davies comorbidity score (IQR)
a 70 1.0 (1.0) 70 2.0 (2.0) 0.009
Median Stoke–Davies comorbidity score (IQR) <1 year
a 14 0.5 (2.0) 14 1.5 (1.0) 0.202
Median Stoke–Davies comorbidity score (IQR) >1 year
a 56 1.0 (1.0) 56 2.0 (2.0) 0.018
Diabetes 13 19% 25 36% 0.023
Late referral 9 13% 22 32% 0.007
Symptom count
a 70 8.6 (3.1) 70 9.7 (3.2) 0.039
SGA 3-5 (mild to moderate malnutrition) 70 16% 70 24% 0.205
Total days in hospital over previous 12 months
a 70 6.6 (8.8) 70 11.0 (18.1) 0.069
Adequately dialysed 70 91% 69 86% 0.274
Pill count
a 70 10.6 (5.3) 65 11.1 (5.7) 0.436
Cognitive function
TMT-B within expected range for age and education level 65 58% 57 68% 0.255
MMSE within expected range for age and education level 70 90% 68 88% 0.739
Blood values
CRP ≤10 mg/L 45 64% 46 63% 0.889
Haemoglobin (g/dL)
a 70 11.6 (1.7) 70 11.7 (1.2) 0.804
Pearson chi-square test used for all other P-values.
aIndependent t-test.
bMann–Whitney.
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point: the SGA provides a reliable, easy to use and well-validated
measure of nutritional status within the dialysis population [22–
24]. In this study, the 7-point scale version [25] was used as it
can detect more subtle differences in nutritional status compared
to the 3-point scale and yet rates patients within the following cat-
egories: well nourished (6–7 points) mildly to moderately mal-
nourished (3–5 points) and severely malnourished (1–2p o i n t s ) .
Nobody scored within this latter category.
(iii) Social networks: A questionnaire was designed to provide a mea-
sure of the support the patient receives and whether they offer sup-
port to anyone within their social sphere [26]. The higher the
social network score, the greater the level of support. The ques-
tionnaire is in Appendix 1.
QOL outcomes
Short Form-12 (SF-12) version 2: the SF-12 is a self assessment of phys-
ical and mental health and has two scores: the Physical Component Sum-
mary scale (PCS) and the Mental Component Summary scale (MCS). It is
an abbreviated version of the SF-36 and was selected as it minimises the
burden of completion in older people. The version used in this study re-
flects QOL over the previous 4 weeks. As there is over 90% agreement
between the SF-12 and the SF-36, population norms for the SF-36 can,
following convention, be used to interpret results for the SF-12 [27,28].
Hospital Anxiety and Depression Scale (HADS): HADS is a screening
tool with scores ranging from 0 (no symptoms) to 21 for either depression
or anxiety. This study focussed on depression scores only. A depression
score of 8 and above indicates the possible presence of clinically impor-
tant depression [29]. Diagnosis using the gold standard for mood disor-
ders (depression) by the Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders was shown to be an independent
predictor of the HADS depression scale in 70 HD patients in the US [30].
The HADS is somewhat shorter than the widely used Beck Depression
Inventory, again minimising burden of completion, making it appropriate
for this patient group.
IllnessIntrusivenessRatingsScale(IIRS):theIIRStoolassessestheim-
pact of chronic illness on aspects of life derived from Flanagan’s research
into what contributes to QOL in the American population at different ages
[31]. The intrusiveness is determined by assessing the extent to which the
illness and/or treatment interferes with 13 life domains (health, diet, work,
active recreation, passive recreation, financial situation, relationship with
partner, sex life, family relations, other social relations, self-expression/
self-improvement, religious expression and community involvement). It
has been validated in different patient groups including end-stage kidney
disease [32]. Scores range from 13 to 91, a higher score indicating a more
intrusive effect of the illness and/or treatment.
Symptom prevalence the presence of 16 symptoms that have been
shown to be prevalent in older people [33] and in patients on dialysis
[34] was assessed by a questionnaire. The symptom questionnaire can
be found in Appendix 2.
Statistical methodologies
Frequencies, independent t-tests, Pearson chi-square and Mann–Whitney
tests were used to compare the participant characteristics between PD and
HD in Tables 1 and 2. Unadjusted QOL outcomes per modality are pre-
sented in Table 3. A sub-analysis is presented in Table 4 showing com-
parisons in those who have been on dialysis for 1 year or less and those
who have been dialysing for more than 1 year. If QOL differences are not
present between HD and PD patients dialysing for <1 year, it could indi-
cate that QOL is not a factor that influences patient’s choice of dialysis
modality. If differences between the two groups only emerge after 1 year,
this could be attributable to the effects of the dialysis regime or other fac-
tors such as the difference in comorbidity scores which is further explored
through regression analyses.
Linear regression analyses were used to ascertain which variables and
interactions significantly influence the SF-12 MCS and PCS scales and
illness intrusion scores (Table 5). Logistic regression was used to identify
the factors associated with having possible clinical depression (HADS
score ≥8) which are shown in Table 6. The IIRS model did not follow
a normal distribution and was subject to log transformation before anal-
ysis. All analyses were undertaken using SPSS 17.0.
Results
Demographics
A total of 140 patients (70 patients each on PD and HD)
aged 65 years and above were recruited. Fifty-eight per-
cent of the PD patients in the sample were on automated
PD and the remainder was on continuous ambulatory PD.
Four out of the 70 HD (6%) patients had been on PD pre-
viously. One patient transferred to HD due to poor ultra-
filtration after >5 years on PD. The three other patients
t r a n s f e r r e dt oH Da f t e r2 –6 months due to peritonitis.
Their QOL did not affect the overall distribution of the re-
Table 3. Unadjusted quality of life outcomes in older PD and HD patients
Quality of life assessments
PD HD
nn P-value
SF-12 PCS
a, mean (SD) 70 36 (12.1) 70 34.3 (9.7) 0.263
SF-12 MCS
a, mean (SD) 70 55.0 (8.4) 70 51.3 (12.9) 0.046
IIRS, median (IQR) 69 22.0 (15.0) 70 26.0 (19.0) 0.006
HADS: depression, median (IQR) 70 4.0 (5.0) 70 6.0 (5.0) 0.003
HADS score >8; prevalence of possible depression (%) 70 10 70 26 0.015
aA higher score indicates better quality of life.
Table 4. Unadjusted quality of life outcomes for those on dialysis for <1year compared to those on dialysis for >1 year
Quality of life outcomes
On dialysis for <1 year
P-value
On dialysis for >1 year
P-value PD (n=14) HD (n=14) PD (n=56) HD (n=56)
SF-12 PCS, mean (SD) 41.1 (11.0) 35.1 (11.5) 0.174 35.2 (12.1) 34.1 (9.3) 0.587
SF-12 MCS, mean (SD) 55.1 (7.4) 58.1 (9.1) 0.346 55.0 (8.7) 49.6 (13.3) 0.013
IIRS, median (IQR) 23.5 (18.5) 27.0 (20.0) 0.550 22.0 (14.0) 26.0 (19.0) 0.005
HADS: depression, median (IQR) 2.5 (4.0) 3.5 (4.0) 0.352 4.0 (4.0) 6.0 (5.0) 0.008
3758 E.A. Brown et al.sults. Ten out of the 70 PD patients had been on HD pre-
viously (five were late referrals who subsequently opted
for PD, five were planned referrals who were on HD either
due to catheter repositioning or who opted for a home
treatment between 4 and 19 months on HD). Twenty-five
percent of patients approached declined to participate in
the study. Table 1 shows that the non-participants, espe-
cially those on PD, were more likely to be from ethnic mi-
nority groups (P=0.041) and to be female (P=0.014). This
partly explains the high male (70%) and white British or
European ethnicity (93%) prevalence seen in the study
sample. The PD and HD participants were otherwise very
comparable in relation to age, gender, time on dialysis, In-
dex of Deprivation, years of education and their social net-
work scores. Other clinical descriptors seen in Table 2
such as dialysis adequacy, nutritional status, cognitive
function, C-reactive protein (CRP) and haemoglobin levels
were also similar. The main differences between the
groups are indicated in Table 2: the PD group had a sig-
nificantly higher prevalence of patients with 0 to 2 comor-
bidities, whilst those on HD had a higher prevalence of ≥3
comorbidities (P=0.003) as well as a higher prevalence of
diabetes (P=0.023) and late referrals (P=0.007). Signifi-
cantly more comorbidities were present in the HD group
compared to the PD group for those dialysing for over
1 year. No difference in comorbidities was seen in those
dialysing for <1 year (Table 2).
QOL outcomes
Table 3 presents the unadjusted QOL outcomes for PD and
HD patients. Although there was no significant difference
in the SF-12 PCS scores, those on PD had better SF-12
MCS scores (P=0.046) with significantly less possible de-
pression (P=0.015) and illness intrusion (P=0.006). Total
number of symptoms was also significantly lower in PD
than HD patients (8.6 and 9.7, respectively, P=0.039). In
assessing the individual items on the Illness Intrusion Rat-
ings Scale, HD patients experienced greater intrusion of
the illness and/or their treatment in relation to their health
(P=0.001) and diet (P≤0.0001) compared to those on PD.
There were not significant differences in the 11 other in-
trusion scales. Table 4 indicates that there were no differ-
ences in the unadjusted values for the SF-12, IIRS or
HADS depression scores in those dialysing for <1 year
between HD and PD. In contrast, for those on dialysis
longer than 12 months, HD patients showed significantly
more illness intrusion (P=0.005), higher depression scores
(P=0.008) and worse SF-12 MCS scores (P=0.013) than
their PD equivalents. To enable a comprehensive compari-
sonbetweenthetwomodalities,theresultswereadjustedfor
multiple factors in regression analyses.
Regression analyses for the SF-12, HADS depression and
Illness Intrusion Ratings Scale
For both the linear and logistic regression modelling, the
following continuous variables were adjusted for: age,
months on dialysis, comorbidity, symptom count and so-
cial network score. In addition, the categorical variables
adjusted for were: gender, modality, nutritional status and
cognitive function. Further modelling (data not presented)
found that late referral and dialysis adequacy had no influ-
ence on QOL outcomes and therefore were excluded from
the final models presented.
Table 5 summarises the results from the linear regres-
sions. The SF-12 PCS scale was found to be influenced
by symptom count alone, with a decrease of 1.7 points
Table 5. Regression analyses for the SF-12 Mental Component Scores, SF-12 Physical Component Scores and Illness Intrusion Ratings Scale (all
adjusted for age, time on dialysis, comorbidity scores, symptom count, social network score, gender, modality, nutritional status and cognitive function)
95% confidence interval
B Standard error Lower Upper P-value
SF-12 PCS
Symptom count −1.692 0.254 −2.194 −1.190 <0.0001
SF-12 MCS
Symptom count −0.948 0.273 −1.489 −0.407 0.001
Males compared to females (when malnourished) 10.513 3.788 3.020 18.006 0.006
Effect of increasing comorbidities (if malnourished) −3.118 1.335 −5.758 −0.477 0.021
Illness Intrusion Ratings Scale
Modality PD compared to HD −0.881 – −0.784 −0.989 0.032
Symptom count 1.054 – 1.036 1.074 <0.0001
Age −0.986 – −0.975 −0.996 0.010
Table 6. Logistic regression for presence of possible depression (HADS ≥8): adjusted for age, time on dialysis, comorbidity scores, symptom count,
social network score, gender, modality, nutritional status and cognitive function
95% confidence interval
Parameter B Standard error Exp (B) Lower Upper P-value
Symptom count 0.446 0.124 1.561 1.224 1.992 <0.0001
Gender: female compared to male 1.773 0.724 5.888 1.424 24.339 0.014
Stoke–Davies comorbidity score 0.660 0.252 1.935 1.182 3.168 0.009
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creasing symptom count was also significantly associated
with a decline in SF-12 MCS (three outliers were excluded
to achieve model of best fit for SF-12 MCS) scores by
0.9 points per symptom (P=0.001). The SF-12 MCS
score was found to be significantly lower in mild to mod-
erately malnourished females compared to equivalent
males (P=0.006). In those who were malnourished, the
SF-12 MCS score declined by 3.1 points for each increase
in comorbidity score (P=0.021). Increasing illness intru-
sion was associated with a greater symptom count (P<
0.0001) and decreasing age (P=0.01). The effect of modal-
ity is illustrated in Figure 1, as it was found to independent-
ly contribute to illness intrusion with poorer scores in those
on HD than in PD (P=0.032).
Logistic regression was used to establish the variables
that are associated with those that have a HADS score of
≥8 (possible depression). Table 6 illustrates that the odds
of having possible depression were found to be 5.9 times
higher for women than for men (P=0.014). For each addi-
tional symptom, the odds of having possible depression in-
creased by a factor of 1.561 (P<0.0001). Similarly for
each additional comorbidity, the odds of having depression
increased by a factor of 1.935 (P=0.009).
Discussion
The results of this study support the use of PD in older pa-
tients. The ultimate study design to establish differences in
the QOL of older patients on PD compared to HD would be
a prospective randomised study. Such a study, however, is
not feasible as it is well established that patients cannot be
randomised between the two dialysis modalities. We have
therefore performed a cross-sectional study and attempted
to match HD to existing PD patients. The results show that
this matching process was successful and the patients were
wellmatchedforage,sex,ethnicityandsocialstatusasmea-
sured by index of deprivation. HD patients, however, did
have a higher comorbidity score than patients on PD. In-
creasing comorbidity did negatively impact the SF-12
MCS scores (only when malnutrition was present) and in-
creased the odds of having possible depression. This study
did not aim to address which individual comorbidities may
have the greatest impact on QOL. Comorbidity did not,
however, impact on the illness intrusion scores, whereas
modality and age did with less illness intrusion in older pa-
tients and those on PD. Comorbidity also did not influence
the SF-12 PCS scores. Gender was found to play a role in
QOL with possible depression (HADS score ≥8) being
more common in women than men on dialysis. Overall,
symptom count was the singlevariable that appeared to in-
fluence all QOL measures studied and had more of an
influence than comorbidity alone.
The main weakness of the current study is that the pa-
tients studied are not representative of the dialysis popula-
tion as a whole. In particular, mainly White Europeans
were recruited. In relation to selection and recruitment of
patients, there may have been a positive selection bias
within the HD population as the most suitable HD patient
was selected to participate if there was more than one ap-
propriate HD match. This selection was determined by the
lead nurse or nephrologist caring for the patient. Another
problem is the cross-sectional design of the study so the
Error Bars: +/- 1 SD
Fig. 1. Illness Intrusion Ratings Scores (IIRS) for PD and HD adjusted for age, time on dialysis, comorbidity scores, symptom count, social network
score, gender, modality, nutritional status and cognitive function. *Significantly less illness intrusion in PD group, P=0.032.
3760 E.A. Brown et al.patients studied are survivors and therefore fitter. This
would have a greater apparent effect in the PD population
as sicker PD patients could have transferred to HD, where-
as sick HD patients are unlikely to transfer to PD. The
study design also makes it difficult to answer the question
as to whether fitter and less depressed patients choose PD
rather than HD. An argument against this is the observa-
tion that QOL measurements in patients who had been
on dialysis for <1 year were the same in the HD and PD
groups; the differences only emerged in patients who had
been on dialysis for more than 1 year (Table 4). In linear
regression analysis in those on dialysis for more than 1 year
(n=112), comorbidity level did not significantly influence
the IIRS and HADS depression scores, whereas modality
(PD) was found to influence these outcomes positively (da-
ta not shown).
The North Thames Dialysis Study, which has been the
only other study exclusively in older people on dialysis
[10], found very similar SF-36 PCS (33.2–34.0) and
MCS (50.7–51.3) results to our study; as in the present
study, these were no different between the HD and PD pa-
tient groups in adjusted analyses. Approximately 18% of
patients in the current study had an HADS score ≥8 (pos-
sible depression). This is of the same order as found in
other studies of patients on dialysis [12,13]. We found that
the significant predictors of possible depression were
symptom count, comorbidity and female sex. None of
these are surprising; a recent meta-analysis has found that
poor self-rated health status and the presence of chronic
disease are the predominant risk factors for depression
among the elderly [35]. The adverse relationship between
being female and QOL has been described in other HD-
related studies [36,37], and the overall population preva-
lence of depression is higher in women than men [38].
As found in the NECOSAD study, symptom score had
an adverse effect on all measures of QOL in the current
study [39].
The choice of dialysis modality has a major impact on
many aspects of an individual’s life. Therefore lifestyle, so-
cial environment and personality, aswell as medical factors,
need to be considered in the decision-making process. Pro-
viding patients with a choice of dialysis modality in itself
appears to improve the QOL [40]. The principal determi-
nants of QOL, as rated by the older person, are the value
of being independent and being in control of one’s own life
[41]. In light of this, PD should be ideally suited to the el-
derly. Interestingly, data from the NECOSAD study [11]
show that where patients are given appropriate education
to make a choice of dialysis modality, 50% chose PD,
though the elderly were less likely to do so. The proportion
of patients >65 years old starting on PD in the three centres
takingpartinthestudywasmuchlowerthanthisandranged
from 6 to 19%. It is therefore possible that some of the HD
patients in our study would have been suitable for PD, par-
ticularlyastherewasnodifferenceinthecognitivefunction,
nutritional status or social network scores between the HD
and PD groups. This potentiallyhas added to the strength of
this study by having patients that possibly would have been
suitable for either modality which may not have occurred in
units that have much higher quotas of patients on PD.
The perception that older patients are more likely to
have barriers to PD related to physical problems, social cir-
cumstances and cognitive dysfunction [42] can result in
the healthcare team believing that PD at home is not fea-
sible in this patient group. This may lead to inappropriate
information being given to the patient which may preclude
further discussion or assistance on how to overcome these
barriers. Indeed, Oliver and Quinn, in a recent review, have
argued that low rates of PD utilisation reflect a breakdown
in the process of care [43]. In a previous study, Oliveret al.
showed that with appropriate multidisciplinary team sup-
port and education, over 50% of an elderly population
deemed eligible for PD chose PD [44].
Conclusion
The findings from this study support the greater use of PD
in older people, and suggest that there may be substantial
under-utilisation in many centres in the UK. The fact that
QOL may well be better on PD due to its potentially lower
intrusion into older peoples’ lives should influence the
content of predialysis education. Improved education
would enable patients to choose dialysis modality based
on how it is going to affect their ability to maintain the
aspects of life they value.
Appendix 1: Social networks questionnaire
￿ Please answer all the questions below, by placing an ‘X’
in the box beside the answer that best describes your
response.
￿ There are no ‘right’ or ‘wrong’ answers, so please
just choose the answer that best fits your own personal
experience.
(1) Who normally lives at home with you?
A. I live with my spouse
B. I live with my family
C. I live with a carer
D. I live alone
(2) Does anyone else in the family live close to your
home?
A. My children
B. Another relative
C. None of the family
(3) Do you have a circle of friends?
A. Yes, a large circle
B. Yes, a small circle
C. No, not many friends
(4) Considering the people living with you, do you think
any of them understand your illness and the dialysis?
A. Yes, they understand well
BOLDE: quality of life of older patients on PD and HD 3761B. Yes, they understand a little
C. No, they don’t understand
D. I live on my own
(5) If you have to come into hospital (other than to dia-
lyse), who would you normally expect to visit you?
A. Several family members and/or friends
B. One or two family members and/or friends
C. Nobody
(6) When you have a problem with your illness, who can
you turn to for help or support?
A. Several family members and/or friends
B. One or two family members and/or friends
C. A doctor or nurse
D. Nobody
(7) Who would turn to you for help or support if they be-
came ill?
A. Several family members and/or friends
B. One or two family members and/or friends
C. Nobody
(8) If you receive some good news, with whom would
you normally share this?
A. Several family members and/or friends
B. One or two family members and/or friends
C. Nobody
(9) Who would come to you with their good news?
A. Several family members and/or friends
B. One or two family members and/or friends
C. Nobody
(10) If you felt generally fed up and miserable, who would
you turn to for support?
A. Several family members and/or friends
B. One or two family members and/or friends
C. Nobody
(11) Who would turn to you for support if they felt fed up
and miserable?
A. Several family members and/or friends
B. One or two family members and/or friends
C. Nobody
Appendix 2: Symptom included in questionnaire
(1) Pain in joints
(2) Blurred vision
(3) Weakness of limbs
(4) Headaches
(5) Light-headedness or dizziness
(6) Cold hands and feet
(7) Cramps in legs
(8) Shortness of breath
(9) Unsteadiness
(10) Dry mouth
(11) Sleep problems
(12) Swelling of legs
(13) Nausea
(14) Itching
(15) Lack of energy
(16) Taste changes
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